Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Insider Jeffrey Dierks Sells 13,125 Shares

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) insider Jeffrey Dierks sold 13,125 shares of the business’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $37.31, for a total value of $489,693.75. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Jeffrey Dierks also recently made the following trade(s):

• On Monday, January 27th, Jeffrey Dierks sold 1,629 shares of Harmony Biosciences stock. The shares were sold at an average price of $38.02, for a total value of $61,934.58.
• On Tuesday, January 21st, Jeffrey Dierks sold 1,123 shares of Harmony Biosciences stock. The shares were sold at an average price of $40.00, for a total value of $44,920.00.
• On Wednesday, January 15th, Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock. The stock was sold at an average price of $37.01, for a total transaction of $388,864.07.

Harmony Biosciences Trading Up 1.9 %

Shares of Harmony Biosciences stock opened at $39.54 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The stock has a market capitalization of $2.26 billion, a PE ratio of 18.74, a P/E/G ratio of 0.51 and a beta of 0.78. Harmony Biosciences Holdings, Inc. has a 1-year low of $28.14 and a 1-year high of $41.61. The company’s fifty day simple moving average is $35.20 and its 200-day simple moving average is $35.22.

Harmony Biosciences (NASDAQ:HRMY) last released its earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.15. The company had revenue of $186.00 million during the quarter, compared to analyst estimates of $184.07 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.63 EPS. As a group, equities analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Institutional Investors Weigh In On Harmony Biosciences

A number of institutional investors have recently added to or reduced their stakes in the stock. Pacer Advisors Inc. boosted its holdings in shares of Harmony Biosciences by 18.2% during the 4th quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company’s stock valued at $78,452,000 after purchasing an additional 351,582 shares during the last quarter. Marshall Wace LLP grew its holdings in Harmony Biosciences by 145.4% during the 2nd quarter. Marshall Wace LLP now owns 305,612 shares of the company’s stock valued at $9,220,000 after buying an additional 181,092 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in Harmony Biosciences by 27.1% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company’s stock worth $26,416,000 after acquiring an additional 140,690 shares during the last quarter. HealthInvest Partners AB raised its holdings in shares of Harmony Biosciences by 335.2% during the 3rd quarter. HealthInvest Partners AB now owns 151,875 shares of the company’s stock worth $6,075,000 after acquiring an additional 116,975 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Harmony Biosciences by 13.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 956,785 shares of the company’s stock valued at $28,871,000 after acquiring an additional 112,197 shares during the last quarter. 86.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on HRMY. Needham & Company LLC reissued a “buy” rating and issued a $52.00 target price on shares of Harmony Biosciences in a research note on Monday, January 13th. Cantor Fitzgerald increased their price objective on Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Raymond James restated an “outperform” rating and issued a $40.00 target price on shares of Harmony Biosciences in a report on Thursday, October 10th. Mizuho upped their price target on shares of Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Thursday, October 10th. Finally, Oppenheimer reissued an “outperform” rating and issued a $59.00 price target (up previously from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $55.00.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.